Sabrina Benjamin, MD
Internal Medicine · Olympia, WANPI 1447280334
Payments from drug & device makers
What this record shows
21 manufacturers reported payments, led by Novartis at 37.6% of the total. Among internal medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $55.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Astrazeneca UK Limited$1K
- Eli Lilly$720
- Janssen Research & Development, LLC$582
- AstraZeneca$344
- Acadia Pharmaceuticals Inc$259
- plus $2K from 15 others
Across 658 payments — averaging $12,150 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4M
- Novartis$2.5M
- AbbVie$428K
- Pfizer$333K
- Janssen Research & Development, LLC$276K
- AstraZeneca$171K
- plus $286K from 10 others
What the payments were for
- Travel & lodging$3,13642%
- Food & beverage$4,24558%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 18 | $2,777 |
| Astrazeneca UK Limited | 7 | $1,096 |
| Eli Lilly | 17 | $720 |
| Janssen Research & Development, LLC | 7 | $582 |
| AstraZeneca | 8 | $344 |
| Acadia Pharmaceuticals Inc | 4 | $259 |
| Johnson & Johnson | 13 | $242 |
| Daiichi Sankyo Inc. | 10 | $210 |
| Sunovion Pharmaceuticals Inc. | 12 | $200 |
| Boehringer Ingelheim | 2 | $140 |
| Pfizer | 7 | $132 |
| AbbVie | 1 | $114 |
| Astellas Pharma US Inc | 5 | $106 |
| Teva Pharmaceuticals USA, Inc. | 5 | $87 |
| Lilly USA, LLC | 4 | $76 |
| Neurocrine Biosciences, Inc. | 1 | $70 |
| UCB, Inc. | 3 | $61 |
| Amgen | 2 | $57 |
| Amarin Pharma, Inc. | 3 | $54 |
| Bayer | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,381 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 221 | $76,775 |
| XareltoRivaroxaban | 103 | $34,931 |
| EntrestoSacubitril/Valsartan | 82 | $28,329 |
| RytaryCarbidopa/Levodopa | 23 | $25,041 |
| EliquisApixaban | 66 | $19,278 |
| TrulicityDulaglutide | 26 | $18,939 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 38 | $11,356 |
| VraylarCariprazine Hcl | 14 | $9,388 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,066 |
| Atorvastatin Calcium | 354 | $6,729 |
| OxycontinOxycodone Hcl | 13 | $6,603 |
| Gabapentin | 227 | $6,510 |
| Glucagon Emergency KitGlucagon | 18 | $6,112 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $6,087 |
| MyrbetriqMirabegron | 25 | $5,683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $140 | $76,775221 claims |
| Johnson & JohnsonXarelto | $242 | $34,931103 claims |
| NovartisEntresto | $2,777 | $28,32982 claims |
| Lilly USA, LLCTrulicity, Olanzapine, Humalog | $76 | $23,403130 claims |
| PfizerEliquis | $132 | $19,27866 claims |
| AbbVieVraylar, Restasis | $114 | $14,55129 claims |
| AstraZenecaSymbicort, Lokelma | $344 | $11,19146 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $5,68325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Olympia
- Shawna PurcellOlympia$294K
- Eric KleinOlympia$23K
- Curtis ReinkeOlympia$14K
- Rebecca MarchOlympia$7K
- Peter ShalitSeattle$1M
- Lawrence LoebBellevue$784K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Alan KellySpokane Valley$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.